Executive leadership at Orchestra BioMed Holdings.
Board of directors at Orchestra BioMed Holdings.
Research analysts covering Orchestra BioMed Holdings.
Recent press releases and 8-K filings for OBIO.
Orchestra BioMed Secures $150 Million in Capital and Provides Program Updates
OBIO
Debt Issuance
New Projects/Investments
- Orchestra BioMed has secured approximately $150 million in capital and commitments since early August, including a public equity offering, strategic investments from Medtronic and Ligand, and a clarified relationship with Terumo.
- Medtronic made an additional equity investment of ~$12 million and committed $20 million in debt, convertible to a royalty credit, which is expected to be taken down in Q2 next year.
- Ligand committed $35 million for a royalty interest in AVIM and Virtue, with $20 million already received and $15 million expected around the same time as the Medtronic payment, plus an additional $5 million in equity.
- The company anticipates releasing data from its AVIM therapy study, partnered with Medtronic for hypertensive heart disease, in late next year or early the following year. Previous MODERATO II data showed an 11 mm Hg absolute reduction in 24-hour ambulatory systolic blood pressure.
- AVIM therapy targets older patients with isolated systolic hypertension, a market opportunity within the 1.1 million pacemakers implanted annually worldwide, where 70%+ of recipients have high blood pressure.
3 days ago
Orchestra BioMed Discusses Recent Capital Raise and Program Updates
OBIO
Debt Issuance
New Projects/Investments
Convertible Preferred Issuance
- Orchestra BioMed secured approximately $150 million in capital and commitments since early August, comprising a $12 million equity investment and $20 million debt commitment from Medtronic, a $35 million royalty-based interest from Ligand, and $46 million from a public equity offering.
- An additional $30 million was raised from Terumo, including an upfront payment of $10 million and a convertible non-voting equity structure.
- The company expects to release data for its AVIM therapy for hypertensive heart disease in late next year or early the following year, with key endpoints being efficacy in reducing systolic blood pressure and safety.
- The AVIM therapy targets a substantial market of over 1.1 million pacemaker implantations annually globally, where more than 70% of patients have high blood pressure.
- Orchestra BioMed's Virtue program employs sirolimus, delivered through a novel liquid-based balloon system, which the company believes is optimal and has shown better early clinical results compared to paclitaxel-based alternatives.
3 days ago
Orchestra BioMed Secures $150 Million in Capital and Provides Program Updates
OBIO
Debt Issuance
New Projects/Investments
Convertible Preferred Issuance
- Orchestra BioMed (OBIO) has raised approximately $150 million in capital and commitments since early August 2025, through four distinct transactions.
- This financing includes strategic investments from Medtronic ($12 million equity, $20 million convertible debt) and Ligand ($20 million royalty interest, $5 million equity, with an additional $15 million royalty commitment), alongside a $46 million public equity offering.
- A clarified relationship with Terumo added $30 million, comprising a $10 million upfront payment and a novel equity structure convertible at a minimum of $12 per share.
- The company expects to release data from its pivotal AVIM study (BackBeat study) for hypertensive heart disease by late 2026 or early 2027.
- AVIM therapy targets a substantial market, with over 1.1 million pacemakers implanted globally each year, and more than 70% of these patients having high blood pressure.
3 days ago
Orchestra BioMed Announces Significant Financing and Clinical Trial Progress
OBIO
New Projects/Investments
Convertible Preferred Issuance
Debt Issuance
- Orchestra BioMed secured approximately $147.6 million in strategic and equity financings since August 2025, including contributions from Medtronic, Ligand, and Terumo, extending its cash runway into the fourth quarter of 2027.
- The company is actively enrolling patients in pivotal IDE trials for both its flagship programs, AVIM Therapy and Virtue SAB.
- Enrollment for the BACKBEAT study (AVIM therapy) is targeted for completion in mid-2026, with potential U.S. commercialization by Medtronic in early 2028.
- Enrollment for the Virtue Trial is targeted for completion in mid-2027.
Nov 13, 2025, 1:30 PM
Orchestra BioMed Secures $147.6 Million in Financing and Provides Business Update
OBIO
Debt Issuance
New Projects/Investments
Guidance Update
- Orchestra BioMed secured $147.6 million in capital and commitments through multiple strategic and equity financings, extending its cash runway into the fourth quarter of 2027.
- The company strengthened its collaboration with Medtronic, entered a new strategic capital relationship with Ligand, and established a new right-of-first refusal agreement with Terumo for Virtue SAB in the coronary market.
- AVIM Therapy received FDA Breakthrough Device Designation and is targeting enrollment completion for its pivotal trial in 2026, with primary endpoint results to follow.
- Enrollment for the Virtue SAB US pivotal coronary trial has launched, with completion targeted for mid-2027.
- The company reported a cash balance of $96 million at the end of the quarter, excluding $30 million received from Terumo on November 7 and $35 million in committed capital expected in Q2 next year.
Nov 12, 2025, 1:00 PM
Orchestra BioMed Holdings, Inc. secures over $147M in financing and updates on pivotal trials
OBIO
New Projects/Investments
Guidance Update
Convertible Preferred Issuance
- Orchestra BioMed Holdings, Inc. has secured over $147 million in strategic-driven financing since August 2025, including $85 million in strategic capital commitments and $62.6 million in equity financing, which is expected to provide a cash runway into Q4 2027.
- The company is advancing two pivotal-stage therapies: AVIM Therapy for hypertension, in collaboration with Medtronic, and Virtue SAB for atherosclerotic artery disease, with a Right of First Refusal agreement with Terumo. Both programs have received FDA Breakthrough Designation.
- These therapies target significant global markets, with AVIM Therapy addressing a >$17 billion annual opportunity and Virtue SAB targeting a >$10 billion annual opportunity.
- The BACKBEAT Global Pivotal Study for AVIM Therapy is currently enrolling, with estimated completion of enrollment in mid-2026, and the Virtue Trial, a U.S. randomized pivotal study for Virtue SAB, is planned for initiation in 2H 2025.
Oct 30, 2025, 11:30 AM
Orchestra BioMed and Terumo Enter New Strategic Agreements Totaling $30 Million
OBIO
New Projects/Investments
Convertible Preferred Issuance
M&A
- Orchestra BioMed Holdings, Inc. (OBIO) and Terumo Medical Corporation (Terumo) entered into new strategic agreements on October 24, 2025, which include the termination of their prior Virtue SAB distribution agreement.
- Terumo will pay OBIO a $10 million fee for a right of first refusal (ROFR) regarding Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) for coronary artery disease.
- Additionally, Terumo will invest an additional $20 million in OBIO through a new series of non-voting preferred stock, convertible into common stock at a minimum of $12 per share.
- OBIO retains all development and distribution rights for Virtue SAB in indications not covered by the ROFR, and has initiated patient enrollment for the Virtue Trial, its U.S. pivotal IDE trial for coronary in-stent restenosis.
Oct 28, 2025, 12:12 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more